Consensus Madrigal Pharmaceuticals, Inc. NYSE

Stocks

US5588681057

Biotechnology & Medical Research

End-of-day quote NYSE			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

09-14	Madrigal Pharmaceuticals, Inc. Announces Opening New Headquarters in Conshohocken, Pa	CI
09-10	Madrigal Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 01:00 PM

650647239a269aab40acf922daf8e.vLw6exp7lEiJMshDlaz7HYBa9ADqBJvu9w4lH_kn_fw.j_poGVI_xQ_oWpl7rOWdV8oPomWzUayhnFFwdqZjsI_983w6bCH2Ou5VkQ~102f73e2725ffd04a2eeefd9522eec61

Analysts' recommendations: Madrigal Pharmaceuticals, Inc.

07-27	Wells Fargo Initiates Madrigal Pharmaceuticals at Overweight With $685 Price Target	MT
07-22	BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542	MT
07-13	Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says	MT
06-11	BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550	MT
05-13	Truist Raises Price Target on Madrigal Pharmaceuticals to $709 From $640, Keeps Buy Rating	MT
02-02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
01-28	Barclays Initiates Coverage on Madrigal Pharmaceuticals With Overweight Rating, $964 Price Target	MT
12-11	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
11-20	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
11-19	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
11-05	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT
11-05	Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral	MT
11-03	Madrigal Pharmaceuticals' Liver Disease Treatment Rezdiffra Outperforms Early Cautious Outlook, BofA Says	MT
11-03	BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445	MT
28/10/25	Madrigal Pharmaceuticals, Inc. to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025	CI
29/09/25	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $560 From $460, Keeps Buy Rating	MT
12/08/25	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $523 From $458, Maintains Buy Rating	MT
05/08/25	Madrigal Pharma's Q2 sales surge on Rezdiffra demand	RE
02/05/25	UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating	MT
28/02/25	B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236	MT
27/02/25	Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says	MT
05/11/24	B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating	MT
01/11/24	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $441 From $411, Maintains Buy Rating	MT
08/08/24	B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating	MT
16/07/24	JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+17.76%
	ARGENX SE					+17.76%
	INSMED INCORPORATED					+59.76%
	WUXI BIOLOGICS (CAYMAN) INC.					+18.28%
	BIONTECH SE					+19.67%
	GENMAB A/S					+15.96%
	PHARMAESSENTIA CORPORATION					+17.42%
	SUMMIT THERAPEUTICS INC.					+57.67%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+28.78%
	Average					+28.12%
	Weighted average by Cap.					+24.51%